publication date: Aug. 4, 2015

NCI CTEP-Approved Trials for the Month of July


The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I

9681: A Phase 1 Study of (Cabozantinib) Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. National Cancer Institute LAO; Apolo, Andrea Borghese (301) 451-1984


AMC-095: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors. AIDS-Associated Malignancies Clinical Trials Consortium; Rajdev, Lakshmi (718) 904-2754


Phase II

A021302: Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study. Alliance for Clinical Trials in Oncology; Shah, Manish Arvind (646) 962-6200


EA2133: InterAACT – An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease. ECOG-ACRIN Cancer Research Group; Eng, Cathy (713) 792-2828


EAI141: Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging. ECOG-ACRIN Cancer Research Group; Jeraj, Robert (608) 263-8619


Continue reading CCL July – NCI CTEP-Approved Trials for the Month of July
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.